Keywords: merck, discontinues, l661, development, co, dropped, its
MERCK DISCONTINUES L661 DEVELOPMENT
Article | 20 September 1993
Merck & Co has dropped its efforts to develop its non-nucleoside reverse transcriptase inhibitor, L661, because the resistance problems seen with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
